An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020-Reference-Cited by-同舟云学术

An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020

Published:2021-12 Issue: Volume: Page:
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Wang Shuhang,Yang Qiuyan,Deng Lan,Lei Qi,Yang Yuqi,Ma Peiwen,Men Yuxin,Yung Bryant C.,Lee Robert J.,Zhang Mengzi,Li Ning

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference48 articles.

1. European Medicines Agency (EMA). European public assessment reports. https://www.ema.europa.eu/sites/default/files/Medicines_output_european_public_assessment_reports.xlsx [accessed May 26, 2021].

2. FDA Office of Pharmaceutical Quality. Center for Drug Evaluation and Research 2020 Annual Report. https://www.fda.gov/media/145830/download. Published 2021 [accessed May 26, 2021].

3. Informa: Pharma intelligence. https://pharmaintelligence.informa.com [accessed May 26, 2021].

4. Clinical development success rates for investigational drugs;Hay;Nat Biotechnol,2014

5. Uzu S. Latest trend of pharmaceutical and medical device regulation in Japan. https://www.pmda.go.jp/files/000236925.pdf. Published October 15, 2020 [accessed May 26, 2021].

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Oncologic Drugs from 2008 to 2023—Differences in Approval and Access between the United States, Europe and Brazil;Current Oncology;2024-08-02

2. Drug supply and assurance: a cross-sectional study of drug shortage monitoring varieties in China;BMC Public Health;2024-07-30

3. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals;Clinical and Translational Science;2024-07

4. Are Turkish pharmaceutical pricing strategies an access barrier to oncology medicines for Türkiye?;Frontiers in Pharmacology;2024-05-10

5. Fabrication of Bacterial Cellulose/Chitosan-MIL-100(Fe) Composite for Adsorptive Removal of Dacarbazine;International Journal of Biological Macromolecules;2024-02